Clinical Quick Reference — Evaluation and Management of Bradycardia and Cardiac Conduction Delay
Understanding the cardiac conduction system is essential for diagnosing and managing bradycardia.
Located at the junction of the superior vena cava and right atrium, the SA node is the heart's primary pacemaker. It generates impulses at 60-100 bpm under normal conditions. The SA nodal artery, arising from the RCA (60% of patients) or LCx (40%), supplies blood to the SA node. Age-related fibrosis and degenerative changes are the most common cause of sinus node dysfunction.
Located in the right atrium near the coronary sinus ostium, the AV node provides the critical delay in conduction between atria and ventricles. Normal AV nodal conduction time is 100-120 ms (PR interval 120-200 ms on ECG). The AV node has three distinct regions: atrial input zone, nodal zone (N region), and nodal-His zone.
The His bundle arises from the AV node and penetrates the fibrous skeleton of the heart. It quickly divides into right and left bundle branches. The right bundle extends down the right ventricular septum; the left bundle divides into anterior and posterior fascicles. Conduction velocity through the His-Purkinje system is 4 m/s, which is faster than through the AV node (0.05 m/s), allowing for rapid ventricular depolarization.
Bradycardia is defined as a resting heart rate <50 bpm in adults (not well-trained athletes). However, normal heart rates of 40-50 bpm can occur in trained athletes and during sleep. The diagnosis of pathologic bradycardia requires correlation with symptoms and clinical context.
| Term | Definition |
|---|---|
| Sinus Bradycardia | Heart rate <50 bpm with normal P-QRS-T configuration |
| Sinus Pause | Sinus node depolarization occurs >3 seconds after the preceding P wave |
| Sinoatrial Exit Block | Blocked conduction between sinus node and atrium; manifests as "group beating" or pauses |
| Chronotropic Incompetence | Failure to achieve ≥80% of age-predicted maximum heart rate (220-age) with exercise |
| First-Degree AV Block | PR interval >200 ms with 1:1 AV conduction (all impulses conduct) |
| Second-Degree AV Block — Mobitz I | Progressive PR prolongation with periodic dropped beat; occurs within AV node |
| Second-Degree AV Block — Mobitz II | Constant PR intervals with periodic dropped beats; occurs below AV node (infranodal) |
| 2:1 AV Block | Every other P wave conducts to ventricles; cannot distinguish Mobitz I vs II |
| High-Grade/Advanced AV Block | ≥2 consecutive P waves fail to conduct but some AV conduction present |
| Third-Degree (Complete) AV Block | No P waves conduct to ventricles; AV dissociation with independent junctional or ventricular escape rhythm |
Right Bundle Branch Block (RBBB): QRS ≥120 ms with rsr', rsR', or rSR' pattern in V1-V2 and S wave in lateral leads. Usually benign unless associated with structural disease.
Left Bundle Branch Block (LBBB): QRS ≥120 ms with broad notched R in I, aVL, V5-V6 and absence of Q waves in I, V5-V6. Indicates underlying cardiac pathology and confers increased risk of progression to complete heart block.
Bifascicular Block: Combination of RBBB + left anterior fascicular block (LAFB) or RBBB + left posterior fascicular block (LPFB). Risk of progression to complete AV block is 1-2% annually.
Trifascicular Block: Bifascicular block + first-degree or second-degree AV block. High risk of progression to complete heart block; pacemaker often indicated.
The 12-lead ECG is essential for evaluating bradycardia. Key parameters to assess:
Indication: Patients with intermittent symptoms (syncope, presyncope, palpitations) or suspected arrhythmias not evident on resting ECG.
Indication: Evaluate for chronotropic incompetence and symptom reproduction during activity.
Indication: Clarify mechanism of bradycardia and assess conduction system function when diagnosis uncertain or when determining need for pacemaker.
Sinus node dysfunction is most common in elderly patients (average age 70-80 years). It typically results from age-related degenerative fibrosis of the sinus nodal tissue and surrounding atrial myocardium. Risk factors include:
Symptoms include syncope, presyncope, dizziness, dyspnea on exertion, fatigue, and impaired exercise tolerance. ECG findings may show sinus bradycardia, sinus pauses >3 seconds, sinoatrial exit block, or alternating with atrial tachycardia ("tachy-brady syndrome").
| Indication | COR | Details |
|---|---|---|
| Documented symptomatic bradycardia from sinus node dysfunction | Class I | Symptoms must include syncope, presyncope, dizziness, or fatigue directly attributable to bradycardia |
| Chronotropic incompetence with symptoms during activities of daily living | Class I | Must have objective evidence of failure to achieve adequate heart rate response on stress testing |
| Symptom-free sinus node dysfunction (bradycardia <40 bpm) | Class III | Pacing not indicated if patient is asymptomatic; continued monitoring appropriate |
| SND in athletes with symptoms and documented pauses >3 seconds | Class IIa | Consider pacing if symptoms interfere with exercise participation despite optimized HR response |
First-degree AV block is characterized by PR interval >200 ms with 1:1 AV conduction. It is common in healthy individuals, athletes, and older adults. Rarely causes symptoms and usually does not require treatment.
Pacemaker Indications: Class IIb only if symptomatic bradycardia is directly attributed to PR prolongation (extremely rare). Most patients with first-degree block require no intervention.
Mobitz I (also called Wenckebach) is characterized by progressive PR prolongation culminating in a dropped P wave. It occurs within the AV node in most cases and typically has a benign prognosis.
| Setting | Outcome | Management |
|---|---|---|
| Asymptomatic, narrow QRS | Excellent — rarely progresses | Observation; no pacemaker |
| Symptomatic (syncope, severe bradycardia) | Variable | Pacemaker if symptoms are documented and related to Mobitz I |
| Infranodal (wide QRS or HV >100 ms) | Worse — risk of progression to complete block | Pacemaker recommended due to risk stratification |
Mobitz II is characterized by constant PR intervals with periodic dropped P waves. It occurs in the infranodal conduction system (His bundle or bundle branches) and has a poor prognosis. Risk of progression to complete heart block is 5-10% per year.
Pacemaker Indication: Class I. Permanent pacemaker is indicated for symptomatic or asymptomatic Mobitz II AV block due to high risk of progression to complete heart block.
In 2:1 AV block, every other P wave conducts to the ventricles. Cannot determine if it is Mobitz I or II on surface ECG alone.
High-grade AV block: Two or more consecutive P waves fail to conduct but some AV conduction is present. Often presents with severe bradycardia and symptoms.
Third-degree (complete) AV block: Complete failure of AV conduction; atria and ventricles beat independently with a junctional or ventricular escape rhythm.
| Type | Escape Rate | Symptoms | Pacemaker Indication |
|---|---|---|---|
| Complete AV Block — Congenital | 40-60 bpm (junctional) | Often asymptomatic if adequate escape rate | Class I if symptoms; Class IIa if escape <40 bpm or widened QRS |
| Complete AV Block — Acquired | <40 bpm (ventricular) | Usually symptomatic; syncope, dyspnea, shock | Class I — pacemaker indicated |
| Acute Infranodal Complete Block | Unstable, slow ventricular escape | Usually severe | Class I — urgent pacemaker needed |
RBBB is common and usually benign, especially in the absence of structural heart disease. It does not typically progress to complete AV block. RBBB alone (without other evidence of conduction disease) rarely requires pacemaker.
Pacemaker Indications for RBBB: Class II indications apply when RBBB is associated with infranodal disease (evidence of prolonged HV interval >100 ms or high-grade AV block on EPS).
LBBB indicates underlying cardiac disease and is associated with higher risk of progression to higher-degree AV block compared to RBBB. LBBB is often seen with cardiomyopathy and may contribute to dyssynchrony.
Pacemaker Indications for LBBB alone: Class III — pacing not indicated for isolated LBBB without evidence of AV block or symptoms.
Bifascicular block (e.g., RBBB + LAFB, or RBBB + LPFB) carries approximately 1-2% annual risk of progression to complete AV block. Management depends on symptoms and EPS findings.
| Clinical Scenario | EPS Finding | COR | Management |
|---|---|---|---|
| Asymptomatic bifascicular block | Normal HV interval (<70 ms) | Class III | Observation; no pacemaker |
| Asymptomatic bifascicular block | Prolonged HV (70-100 ms) | Class IIb | Consider pacemaker; monitor closely or obtain EPS |
| Asymptomatic bifascicular block | HV >100 ms or high-grade AVB on EPS | Class I | Pacemaker indicated |
| Symptomatic bifascicular block (syncope) | Any | Class I | Pacemaker indicated if syncope attributable to conduction block |
Trifascicular block (bifascicular block + first-degree or second-degree AV block) indicates severe conduction system disease.
Pacemaker Indication: Class I. Pacemaker is indicated for trifascicular block with symptomatic bradycardia or significant conduction disease documented on EPS (HV >100 ms or inducible complete AVB).
| Agent | Dose | Mechanism | Efficacy | Cautions |
|---|---|---|---|---|
| Atropine | 0.5 mg IV q3-5min, max 3 mg | Anticholinergic; blocks vagal effects | Best for nodal block; limited for infranodal | Paradoxical bradycardia at low doses; less effective in transplant |
| Dopamine | 2-20 mcg/kg/min IV infusion | Beta-1 agonist; increases contractility and HR | Good for most bradycardias | Tachycardia, arrhythmias, hypertension at higher doses |
| Isoproterenol | 2-10 mcg/min IV infusion | Beta-1 and beta-2 agonist | Effective but less preferred | Increases myocardial oxygen demand; risk of ischemia |
| Epinephrine | 0.3-1 mg IV (5 min intervals) in arrest | Non-selective adrenergic agonist | For asystolic bradycardia/cardiac arrest | Severe hypertension, myocardial ischemia risk |
The following table summarizes Class of Recommendation (COR) for permanent pacemaker implantation in various bradycardia and conduction disorders. COR I = strong recommendation; COR II = moderate recommendation; COR III = not recommended.
| Condition | COR | Rationale |
|---|---|---|
| Sinus Node Dysfunction with Symptoms | I | Documented symptomatic bradycardia from SND with syncope, presyncope, dizziness, or heart failure |
| SND with Chronotropic Incompetence | I | Symptoms during ADL with objective evidence of inadequate HR response to exercise |
| SND, Asymptomatic with Pause >3 sec | III | No pacemaker if asymptomatic; monitor and re-evaluate |
| Mobitz I (Nodal) with Symptoms | I | If symptoms documented and directly attributable to AV block |
| Mobitz I (Infranodal) based on HV | I | HV >100 ms or infranodal location confirmed; high risk of progression |
| Mobitz II AV Block | I | Always indicated; high risk of progression to complete block regardless of symptoms |
| 2:1 AV Block with Wide QRS | I | Likely infranodal; indicates Mobitz II physiology |
| Complete Heart Block — Symptomatic | I | Syncope, severe bradycardia, hemodynamic compromise |
| Complete Heart Block — Congenital | I | If symptoms or escape rate <40 bpm or wide QRS escape |
| Bifascicular Block, Normal HV, Asymptomatic | III | Observation adequate; no pacemaker unless progression documented |
| Bifascicular Block, HV >100 ms | I | High risk of complete AVB; pacemaker indicated |
| Bifascicular Block with Syncope | I | If syncope attributable to conduction block and other causes excluded |
| LBBB Alone, Asymptomatic | III | No pacemaker; LBBB alone does not warrant pacing |
COR I: Pacemaker indicated if patient has objective evidence of chronotropic incompetence (failure to reach 80% age-predicted max HR) and develops symptoms (dyspnea, fatigue, syncope) during normal activities.
COR I: Pacemaker indicated for patients with Duchenne muscular dystrophy or other neuromuscular disease with documented symptomatic bradycardia or conduction abnormality.
COR I: Pacemaker indicated for cardiac sarcoidosis, amyloidosis, hemochromatosis, or other infiltrative disease with documented symptomatic bradycardia or high-grade AV block.
COR IIa: Pacemaker may be considered in obstructive sleep apnea patients with severe symptomatic bradycardia or AV block if bradycardia directly related to apneic episodes and not resolved by OSA treatment.
COR I: Pacemaker indicated if high-degree or complete AV block persists beyond 7 days post-operatively.
COR IIa: Consider pacemaker if documented pauses >3 seconds or marked bradycardia associated with syncope during exercise and limiting athletic participation. Diagnose after excluding other causes.
| Mode | Pacing | Sensing | Use Case | Advantages | Disadvantages |
|---|---|---|---|---|---|
| VVI | Ventricle | Ventricle | Permanent AF, symptomatic bradycardia | Simple, cost-effective, single lead | Loss of AV synchrony; higher AF incidence; RV pacing burden |
| AAI | Atrium | Atrium | SND, normal AV conduction | Preserves AV synchrony; physiologic | Requires normal AV conduction; limited use if conduction disease |
| DDD | Both atrium and ventricle | Both chambers | SND with AV block, AV block | Dual-chamber; maintains AV synchrony; optimal hemodynamics | More complex; higher cost; dual leads required |
| DDDR | Both + rate adaptive | Both chambers | SND, chronotropic incompetence, active patients | Increases heart rate with activity | Most complex; highest cost |
COR I: Dual-chamber pacing (DDD or DDDR) is preferred over single-chamber ventricular pacing (VVI) in patients with SND or AV block AND intact or partially intact AV conduction. This recommendation is based on:
COR I: Rate-adaptive pacing should be considered in patients with chronotropic incompetence who require frequent pacing and are active. Benefits include improved exercise capacity and symptom relief.
Traditional right ventricular apical pacing has been the standard approach for decades. However, chronic high-percentage RV apical pacing is associated with:
COR IIa: RV septal pacing may be considered as an alternative to RV apical pacing, particularly in patients who require high percentage of RV pacing. Some studies suggest improved hemodynamics and reduced adverse outcomes compared to apical pacing, though evidence is not conclusive.
COR IIb: His-bundle pacing may be considered in patients with:
Advantages: Preserves normal ventricular activation sequence; maintains narrow QRS; physiologic conduction.
Limitations: Requires specialized equipment and expertise; longer procedure time; limited long-term follow-up data; potential for higher thresholds.
COR IIb: LBBP (also called conduction system pacing) via left ventricular septum may be considered as an alternative to RV apical or septal pacing. Emerging evidence suggests benefits similar to His-bundle pacing with potentially more stable thresholds.
Advantages: Achieves narrow QRS pacing; preserves physiologic conduction; potentially more durable than His-bundle.
Limitations: Relatively new technique; requires specialized training; need for transseptal approach; potential for retrograde conduction and pacemaker-mediated tachycardia.
Standard placement is in the right atrial appendage (RAA). Alternative sites (Bachmann's bundle, septal) may be considered in specific clinical scenarios but RAA remains the gold standard.
Athletes commonly develop asymptomatic bradycardia (HR 40-50 bpm) and sinus pauses due to enhanced vagal tone and stroke volume. This is a normal adaptation and does not warrant treatment.
Pacemaker Indication: Consider pacing only if athlete has documented symptomatic bradycardia (syncope during exercise) with significant pauses and other causes excluded. Pacemaker should not unnecessarily restrict athletic participation.
Obstructive sleep apnea (OSA) can cause severe bradycardia, AV block, and asystole during apneic events. Management focuses on treating the underlying sleep apnea with CPAP or other OSA therapies.
Pacemaker Indication: COR IIa — consider if symptomatic bradycardia or AV block persists despite adequate OSA treatment, or if patient is not a candidate for OSA therapy.
Temporary AV block is common after cardiac surgery due to edema and trauma to the conduction system. Management depends on timing of block occurrence and presence of symptoms.
Recommendation: Temporary pacing is used acutely. Permanent pacemaker indicated only if high-degree or complete AV block persists beyond 7 days post-operatively. Some centers use 10-14 days as cutoff.
Patients with Duchenne muscular dystrophy, myotonic dystrophy, Emery-Dreifuss muscular dystrophy, and other neuromuscular disorders are at risk for progressive conduction system disease and sudden cardiac death.
Recommendation: COR I — pacemaker indicated for documented symptomatic bradycardia, high-degree AV block, or infranodal conduction disease (HV >100 ms) regardless of symptoms. Implantable defibrillator consideration based on disease type and cardiac involvement.
Cardiac sarcoidosis, amyloidosis, hemochromatosis, Chagas disease, and other infiltrative conditions can cause conduction abnormalities and bradycardia.
Recommendation: COR I — pacemaker indicated for symptomatic bradycardia or documented high-degree AV block. May also require ICD if reduced ejection fraction or evidence of scar on imaging.
Bradycardia in adult congenital heart disease (ACHD) patients may result from surgical damage to conduction tissue, sequelae of repair, or progressive degenerative disease.
Recommendation: Pacemaker indications similar to non-congenital disease. CRT with or without ICD consideration based on systemic RV or residual LV dysfunction.
Bradycardia and conduction disease are common in elderly. Age alone should not preclude pacemaker implantation if indications are present. Careful consideration of comorbidities and life expectancy is warranted.
Recommendation: Standard pacemaker indications apply. Benefits of pacing (symptom relief, reduced mortality) typically outweigh risks even in octogenarians and nonagenarians.
Many commonly prescribed medications can cause or exacerbate bradycardia and conduction abnormalities. Careful review of medications is essential in all bradycardia workups.
| Drug Class | Mechanism | Effects | Management |
|---|---|---|---|
| Beta-Blockers | Beta-1 antagonism; slows SA and AV nodal conduction | Bradycardia, AV block, sinus pauses | Reduce dose or discontinue; consider alternative antihypertensive |
| Non-DHP Calcium Channel Blockers | AV nodal depression; slows atrial conduction | AV block, bradycardia, rarely sinus node dysfunction | Reduce dose or switch to DHP (dihydropyridine) class |
| Digoxin | Increases vagal tone; slows AV nodal conduction | AV block (especially Mobitz I), bradycardia | Check levels; reduce if elevated; may need pacing if severe block |
| Antiarrhythmic Drugs | Class I and III agents slow conduction | Bradycardia, AV block, sinus node dysfunction | Reduce dose or discontinue; careful monitoring required |
| Lithium | Direct conduction system toxicity | Sinus node dysfunction, AV block, arrhythmias | Lithium levels; discontinue if possible; consider pacemaker if symptomatic |
| Adenosine | Adenosine receptor activation; transient AV block | Temporary AV block during IV administration | Expected and reversible; caution in patients with preexisting AV block |
| Amiodarone | Multiple effects: beta-block, Ca channel block, K channel block | Bradycardia, AV block, sinus node dysfunction | Reduce dose; may require pacemaker for severe bradycardia |
The following calculators are useful tools for risk stratification and clinical decision-making in cardiovascular disease. Click on any calculator to access the full tool.
Determine eligibility for cardiac resynchronization therapy based on QRS duration, LVEF, and symptom status.
Estimate likelihood of favorable response to CRT based on clinical and imaging parameters.
Assess degree of pacemaker dependence and intrinsic rhythm reserve.
Determine need for ICD implantation for primary prevention of sudden cardiac death.
Calculate QT interval corrected for heart rate using Bazett, Fridericia, or Framingham formula.
Calculate estimated glomerular filtration rate using CKD-EPI equation.
Calculate creatinine clearance using Cockcroft-Gault equation for medication dosing.
Assess stroke risk in patients with atrial fibrillation; guide anticoagulation decisions.
Assess bleeding risk in patients with atrial fibrillation on anticoagulation therapy.